Aurélie leads the Precision Medicine Practice at Bionest Partners, a Life Sciences Consulting firm in New York and Paris. She works extensively in the field of biomarker and companion diagnostics, in oncology as well as other therapeutic areas, supporting pharmaceutical, biotech, and diagnostic companies on their diagnostic and companion diagnostic go-to-market strategy. Aurélie has advised clients on their strategy across diagnostic technologies - including emerging platforms such as artificial-intelligence based diagnostics, liquid biopsy, multi-omics, etc. She has developed a specific expertise in next generation sequencing, with a focus on the go-to-market strategy requirements for NGS-based CDx tests in Europe from lab and test model for deployment to stakeholder education gaps and market access considerations. Aurélie holds an Engineering Degree and MsC in cell and molecular biology from the Ecole Polytechnique (Paris) and a M.Phil. in bioscience enterprise from The University of Cambridge.